Work

Subtypes of Dry Eye Disease: Mechanical Mechanisms of the Carotid Sheath Under Investing Fascia Release—A Testable Hypothesis

Year: 2026
Type: preprint
Abstract: Objective: This article argues, from anatomical and mechanical perspectives, that release of the investing fascia has a plausible mechanistic basis and is testable as an intervention for subtypes of dry eye disease. As defined here, release of the investing fascia refers to mechanical intervention on the anterior cervical connective tissue network rather than transection of a discrete fascial layer. These subtypes respond poorly to conventional therapy centered on tear film hyperosmolarity and inflammation and often coexist with abnormal neck–shoulder posture, forward head posture, or neck stiffness. If an upstream fascial mechanical variable amenable to targeted intervention exists, release of the investing fascia may offer these patients an approach distinct from conventional anti-inflammatory or tear supplementation therapy.The argument proceeds along three lines. First, the anatomical line of evidence: the relationship between the investing fascia and the carotid sheath is not a homogeneous direct cable but a layer-specific composite relationship. Adult cadaveric studies suggest that the investing fascia may not exist as an independent continuous layer and that whether a stable fusion interface forms between the carotid sheath and the pretracheal layer remains histologically controversial. These same studies suggest that the midcervical sheath wall is composed mainly of the superficial layer of the prevertebral fascia and that the anterior sheath wall at the skull base–upper cervical segment is formed by the convergence of a four-layer fascial complex comprising the TVSF, SPF, BPF, and LCF. Accordingly, release of the investing fascia should be understood anatomically as mechanical intervention on the anterior cervical connective tissue network, including the superficial layer of the prevertebral fascia and the four-layer complex at the skull base–upper cervical segment, rather than transection of a single fascial layer.Second, the mechanical line of evidence: the anterior cervical connective tissue network is continuous with or tightly connected to the sheath wall, so abnormal passive tension can be transmitted to the sheath wall through this network. In vivo human studies suggest that the efficiency of transmission from external mechanical input at the neck to the carotid artery region is on the order of 60%–90%. After ultrasound-guided hydrodissection, fascial shear modulus decreases significantly under stretch, providing a measurable mechanical precedent for the upstream step of release leading to tension reduction.Third, the downstream-effect line of evidence: if release reduces the abnormal mechanical constraint on the sheath wall and intrasheath structures, six types of effects can be expected according to the four downstream pathways of H3—increased ocular blood supply, improved venous return, improved lymphatic return, reduced intraocular pressure, reduced sympathetic excitability, and increased vagal excitability. Among these, the physiological chain of sympathetic excitation leading to distal arterial constriction and insufficient blood supply, and the hypothesis chain of release leading to reduced sympathetic tone and improved blood supply, are mechanistically linked. The in vivo experiments by Abe et al. in cats, in which sectioning or stimulation of the cervical sympathetic nerve reversibly altered choroidal blood flow, provide a functional-possibility template for the intermediate step of altered sympathetic tone leading to altered ocular blood flow. However, the species, nature of stimulation, and target limitations of this template mean that it does not constitute evidence of mechanical sensitivity and does not change the evidence grade for H2 or H4.The available clinical indirect evidence—a needle-knife RCT, a network meta-analysis, a single-arm hydrodissection study, and a pilot osteopathic RCT—involves composite interventions, unspecified targets, absence of controls, or mismatched populations and endpoints. It therefore cannot be used for mechanistic attribution, although it may serve as an early signal that release may be accompanied by changes in ocular surface, blood flow, or intraocular pressure. On this basis, this article proposes a testable mechanistic framework. In this framework, release of the investing fascia is the intervention, sheath deformation and ocular surface metrics are primary endpoints, the six types of downstream effects are secondary endpoints, and sham-intervention control plus synchronous measurement of ocular surface PIEZO1/Piezo1 pathway are dual exclusion conditions for attribution. The anatomical and mechanical plausibility of this framework is relatively high, but clinical efficacy has not yet been confirmed by controlled trials with clearly defined targets.
Language: English
Open Access status: green
OpenAlex ID: W7225919486
Cites:
Cited by:
Related to: 10